HomeDBVT • NASDAQ
DBV Technologies SA - ADR
add
Financials
Income Statement
Revenue
Net Income
Revenue
Net income
| (USD) | Mar 2025info | Y/Y change |
|---|---|---|
Revenue | 753.00K | -46.48% |
Operating expense | 27.37M | -8.66% |
Net income | -27.08M | 0.97% |
Net profit margin | -3.60K | -85.03% |
Earnings per share | -0.23 | 91.18% |
EBITDA | -25.67M | 9.96% |
Effective tax rate | — | — |
Balance Sheet
Total Assets
Total Liabilities
Total assets
Total liabilities
| (USD) | Mar 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 12.96M | -87.23% |
Total assets | 50.56M | -65.34% |
Total liabilities | 47.69M | 39.27% |
Total equity | 2.87M | — |
Shares outstanding | 136.72M | — |
Price to book | 382.67 | — |
Return on assets | -114.52% | — |
Return on capital | -299.45% | — |
Cash Flow
Net Change in Cash
Net change in cash
| (USD) | Mar 2025info | Y/Y change |
|---|---|---|
Net income | -27.08M | 0.97% |
Cash from operations | -19.67M | 43.31% |
Cash from investing | -375.00K | 82.41% |
Cash from financing | 45.00K | 172.58% |
Net change in cash | -19.49M | 51.07% |
Free cash flow | -9.34M | 66.16% |
Previous close
$11.48
Day range
$10.78 - $11.66
Year range
$2.20 - $12.78
Market cap
341.02M USD
Avg Volume
106.02K
About
DBV Technologies SA is a publicly owned French biopharmaceutical firm headquartered in Bagneux, France. DBV Technologies is known for developing "Viaskin" technology for administering allergens or antigens to intact skin while avoiding any transfer to the blood. Viaskin Peanut clinical development has received Fast Track designation from the US Food and Drug Administration. Wikipedia
Founded
Mar 29, 2002
Website
Employees
106
